1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Northern Europe Keeps Up The Pressure On Biosimilar Infliximab Switching

 
• By Ian Schofield

Northern European efforts to boost the use of biosimilar infliximab rather than Janssen's Remicade are gathering pace, with the Norwegian NOR-SWITCH study having been extended by 26 weeks to complete the switch from Remicade to Celltrion's biosimilar, Remsima, and a number of similar studies being conducted by both industry and non-commercial sponsors in the Netherlands.

Northern European efforts to boost the use of biosimilar infliximab rather than Janssen's Remicade are gathering pace, with the Norwegian NOR-SWITCH study having been extended by 26 weeks to complete the switch from Remicade to Celltrion's biosimilar, Remsima, and a number of similar studies being conducted by both industry and non-commercial sponsors in the Netherlands.

A key aim of these efforts is of course to reap the rewards in terms of lower spending on the increasingly expensive biotech medicines

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

GSK Pays $1.2bn For Phase III-Ready MASH Contender

 
• By Andrew McConaghie

The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.

More from Therapy Areas

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.